Deinove (ALDEI.PA) Stock Price & Overview
EPA:ALDEI • FR0010879056
Current stock price
The current stock price of ALDEI.PA is 0.0265 EUR. Today ALDEI.PA is up by 13.25%. In the past month the price decreased by -3.28%. In the past year, price decreased by -94.66%.
ALDEI.PA Key Statistics
- Market Cap
- 873.857K
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.24
- Dividend Yield
- N/A
ALDEI.PA Stock Performance
ALDEI.PA Stock Chart
ALDEI.PA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ALDEI.PA. When comparing the yearly performance of all stocks, ALDEI.PA is a bad performer in the overall market: 99.74% of all stocks are doing better.
ALDEI.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALDEI.PA. Both the profitability and financial health of ALDEI.PA have multiple concerns.
ALDEI.PA Earnings
ALDEI.PA Forecast & Estimates
9 analysts have analysed ALDEI.PA and the average price target is 0.61 EUR. This implies a price increase of 2209.43% is expected in the next year compared to the current price of 0.0265.
For the next year, analysts expect an EPS growth of -28.21% and a revenue growth 100% for ALDEI.PA
ALDEI.PA Groups
Sector & Classification
ALDEI.PA Financial Highlights
Over the last trailing twelve months ALDEI.PA reported a non-GAAP Earnings per Share(EPS) of -0.24. The EPS decreased by -15.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALDEI.PA Ownership
ALDEI.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SY1 | SYMRISE AG | 18.43 | 10.432B | ||
| AKU1 | AKZO NOBEL N.V. | 12.75 | 8.802B | ||
| AKZA | AKZO NOBEL N.V. | 13 | 8.706B | ||
| 1EVK | EVONIK INDUSTRIES AG | 13.57 | 7.861B | ||
| EVK | EVONIK INDUSTRIES AG | 13.83 | 7.806B | ||
| SYENS | SYENSQO SA | 14.15 | 5.44B | ||
| WCH | WACKER CHEMIE AG | 346.35 | 4.743B | ||
| AKE | ARKEMA | 12.65 | 4.499B | ||
| UMI | UMICORE | 12.61 | 4.255B | ||
| NVJP | UMICORE | 12.21 | 4.228B | ||
| ACT | ALZCHEM GROUP AG | 28.27 | 1.903B | ||
| RBT | ROBERTET SA | 16.39 | 1.749B | ||
| CRBN | CORBION NV | 12.9 | 1.097B |
Related stock screener links
View all stocks in the Specialty Chemicals Industry | View all stocks in the Materials Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALDEI.PA
Company Profile
Deinove SA is a biotechnology company, which engages in the development of new-generation anti-infective antibiotics and bioactives. The company is headquartered in Grabels, Occitanie and currently employs 44 full-time employees. The company went IPO on 2010-04-21. The company specializes in the development and commercial exploitation of processes for production of biofuels and other compounds of industrial or pharmaceutical value. The processes developed by Deinove use the natural properties of Deinococcus bacteria. The green chemistry process includes the production of organic acids, such as succinic, lactic, fumaric and butyric acids used in the petrochemical, pharmaceutical, cosmetics and food industries. In addition, the Company is engaged in the production of antibiotics and antifungal agents. Deinove SA operates with such industrial companies as Tereos, CNRS, VTT, BENP-Lillebonne and Nosopharm, among others. The firm's main shareholder is Fonds Truffle Capital. The company operates through DEINOBIOTICS and Deinobiotics SAS, among others.
Company Info
IPO: 2010-04-21
Deinove
Cap Sigma / ZAC Euromedecine II, 1682 rue de la Valsiere
Grabels OCCITANIE FR
Employees: 44
Phone: 33448190100.0
Deinove / ALDEI.PA FAQ
What does ALDEI do?
Deinove SA is a biotechnology company, which engages in the development of new-generation anti-infective antibiotics and bioactives. The company is headquartered in Grabels, Occitanie and currently employs 44 full-time employees. The company went IPO on 2010-04-21. The company specializes in the development and commercial exploitation of processes for production of biofuels and other compounds of industrial or pharmaceutical value. The processes developed by Deinove use the natural properties of Deinococcus bacteria. The green chemistry process includes the production of organic acids, such as succinic, lactic, fumaric and butyric acids used in the petrochemical, pharmaceutical, cosmetics and food industries. In addition, the Company is engaged in the production of antibiotics and antifungal agents. Deinove SA operates with such industrial companies as Tereos, CNRS, VTT, BENP-Lillebonne and Nosopharm, among others. The firm's main shareholder is Fonds Truffle Capital. The company operates through DEINOBIOTICS and Deinobiotics SAS, among others.
What is the stock price of Deinove today?
The current stock price of ALDEI.PA is 0.0265 EUR. The price increased by 13.25% in the last trading session.
Does Deinove pay dividends?
ALDEI.PA does not pay a dividend.
How is the ChartMill rating for Deinove?
ALDEI.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for ALDEI stock?
Deinove (ALDEI.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.24).
What is the expected growth for ALDEI stock?
The Revenue of Deinove (ALDEI.PA) is expected to grow by 100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.